Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma

• Published in: World journal of surgical oncology Vol. 21; no. 1; pp. 33 - 8
• Main Authors: Cheng, Daoan, Zhao, Weiqing, Chen, Rui, Li, Dong, Tang, Shuxian, Fang, Cheng, Ji, Mei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.02.2023; BioMed Central; BMC
• Subjects: Adjuvant treatment; Anti-programmed death-1 (PD-1); Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biopsy; Cancer; Cancer therapies; Care and treatment; Chemoradiotherapy; Chemotherapy; Chi-square test; Continuity (mathematics); Diagnosis; Disease-Free Survival; Dosage and administration; Esophageal cancer; Esophageal carcinoma; Esophageal Neoplasms - pathology; Esophagus; Humans; Immunochemotherapy; Medical prognosis; Monoclonal antibodies; Neoadjuvant Therapy - methods; Neoadjuvant treatment; Neoplasm Recurrence, Local - pathology; Neoplasm Staging; Patients; PD-1 protein; Programmed Cell Death 1 Receptor; Radiation therapy; Remission; Retrospective Studies; Software; Surgery; Tumors; China; United States > US; Immunochemotherapy; Anti-programmed death-1 (PD-1); Esophageal cancer; Neoadjuvant treatment
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-023-02915-z

Neoadjuvant chemotherapy (nCT) or neoadjuvant chemoradiotherapy followed by surgery has been recommended as standard treatment in patients with locally advanced esophageal cancer (LAEC). But the risk of tumor recurrence still remained, and many patients refused or abandoned radiotherapy because of the intolerable adverse effects in China. Neoadjuvant immunochemotherapy (nICT) followed by surgery has become an emerging treatment in patients with esophageal cancer. There was still no consensus on whether nICT was superior to nCT alone in patients with esophageal cancer. In this retrospective study, patients with resectable esophageal cancer who received surgery after nICT (n=26, 40%) or nCT alone (n=39, 60%) were included. The patients were classified as nICT or nCT arm. The primary endpoints were pathological tumor response (PTR) and event-free survival (EFS). The different clinic-pathological features were compared by the Kruskal-Wallis test for continuous variables and the Chi-square (χ ) test for categorical variables. Kaplan-Meier curves were used to estimate EFS from the date of treatment to recurrence or death. All tests were 2-sided with a significative P-value defined <.05. Three (11.5%) of the 26 patients achieved pathological complete remission (pCR) in the nICT group, and four (10.3%) of the 39 patients achieved pCR in the nCT group, respectively (P=1.000). Six (23.1%) of the 26 patients achieved major pathological response (MPR) in the nICT group, and 11 (28.2%) of the 39 patients achieved MPR in the nCT group, respectively (P=0.645). Downstaging was achieved in 13 (44.8%) patients in the nICT group and 16 (55.2%) patients in the nCT group, respectively (P=0.732). To verify the tumor regression grade (TRG) results, we compared them with MPR and pCR, which showed a significant dependency (P< 0.001). Patients who achieved downgrading showed better MPR and pCR rates (P<0.001 and P =0.010). There was no significant difference in EFS between the nICT and nCT groups (HR=1.011, 95% CI: 0.421-2.425, P = 0.981). Neoadjuvant PD-1 blockade combined with chemotherapy was not superior to chemotherapy alone for patients with resectable locally advanced esophageal carcinoma. However, more studies with long-term follow-up were needed to confirm this result.